In this study, human insulin was compared with two of its analogs—LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin—with respect to bioavailability and metabolic effectiveness. Absorption from the subcutaneous site was determined using kinetic parameters from the washout curve, following intravenous infusion of insulin or analog. Absorption was found to be more rapid for the two analogs, with 90% absorption by 100 min for the analogs and by 180 min for insulin. Total absorption was 97 ± 10% for insulin, 99 ± 7% for LysB28ProB29-human insulin, and 93 ± 12% for AspB10LysB28ProB29-human insulin. Bioactivity was assessed from the glucose infusion and using tracer-determined metabolic clearance rates (MCRs) and glucose production rates. The fractional glucose requirements (relative to the total amount infused) increased more rapidly for the two analogs than for insulin, with 50% of the glucose infused by 105 min for both analogs vs. 145 min for insulin. The total amount of glucose required was, however, significantly less (19.7 ± 1.5 mmol/kg) for AspB10LysB28ProB29-human insulin than for either LysB28ProB29-human insulin (25.9 ± 3.0 mmol/kg) or human insulin (27.8 ± 2.6 mmol/kg). The glucose requirements were reflected in a lower MCR for AspB10LysB28ProB29-human insulin but equivalent decreases in the rates of glucose production. Thus both analogs demonstrated more rapid rates of absorption, onset, and termination of action, but were not completely bioequivalent, with AspB10LysB28ProB29-human insulin demonstrating a 25% decrease in bioactivity.
Skip Nav Destination
Article navigation
Original Articles|
April 01 1997
Bioavailability and Bioeffectiveness of Subcutaneous Human Insulin and Two of its Analogs—LysB28ProB29-Human Insulin and AspB10LysB28ProB29-Human Insulin—Assessed in a Conscious Pig Model Free
Jerry M Radziuk;
Jerry M Radziuk
Ottawa Civic Hospital, University of Ottawa
Ottawa, Canada
Search for other works by this author on:
Jill C Davies;
Jill C Davies
Ottawa Civic Hospital, University of Ottawa
Ottawa, Canada
Search for other works by this author on:
W Susan Pye;
W Susan Pye
Ottawa Civic Hospital, University of Ottawa
Ottawa, Canada
Search for other works by this author on:
James E Shields;
James E Shields
Lilly Research Laboratories
Indianapolis, Indiana
Search for other works by this author on:
Richard D DiMarchi;
Richard D DiMarchi
Lilly Research Laboratories
Indianapolis, Indiana
Search for other works by this author on:
Ronald E Chance
Ronald E Chance
Lilly Research Laboratories
Indianapolis, Indiana
Search for other works by this author on:
Address correspondence and reprint requests to Dr. Jerry Radziuk, Ottawa Civic Hospital, 1053 Carling Ave., Ottawa, ON, Canada K1Y 4E9.
1
MCR, metabolic clearance rate.
Diabetes 1997;46(4):548–556
Article history
Received:
June 18 1996
Revision Received:
November 14 1996
Accepted:
November 14 1996
PubMed:
9075793
Citation
Jerry M Radziuk, Jill C Davies, W Susan Pye, James E Shields, Richard D DiMarchi, Ronald E Chance; Bioavailability and Bioeffectiveness of Subcutaneous Human Insulin and Two of its Analogs—LysB28ProB29-Human Insulin and AspB10LysB28ProB29-Human Insulin—Assessed in a Conscious Pig Model. Diabetes 1 April 1997; 46 (4): 548–556. https://doi.org/10.2337/diab.46.4.548
Download citation file:
269
Views